决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy.
Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy.
开发具有改进的灵活靶向性和可控活性的通用CARs是迫切需要的。
开发具有改进的灵活靶向和可控活性的通用CARs迫在眉睫。虽然几项研究已表明CD16a与单克隆抗体串联构建通用CAR-T细胞的潜力,但它们之间的弱亲和力是限制疗效的因素之一。在此,我们通过使用对IgG1抗体具有不同亲和力的Fc受体(即CD16a、CD32a和CD64)构建通用CARs,系统研究了Fc受体(Fc R)亲和力对CAR-T细胞特性的影响。我们证明,这些通用CAR-T细胞对肿瘤细胞的活性可以被IgG1抗体重新定向和调控。在异种移植小鼠中,具有最高亲和力的64CAR嵌合Jurkat细胞与herceptin联合在HER2低表达U251 MG模型中显示出显著的抗肿瘤效果。然而,在CD20高表达Raji模型中,64CAR引起CAR-T细胞的过度激活,导致细胞因子释放综合征(CRS)和抗肿瘤活性下降,而具有中等亲和力的32CAR带来了最佳疗效。我们的工作扩展了关于基于Fc R的通用CAR-T细胞的认识,并表明只有具有适当亲和力的Fc RCAR才能为CAR-T细胞提供最佳的抗肿瘤优势。
Developing universal CARs with improved flexible targeting and controllable activities is urgently needed. While several studies have suggested the potential of CD16a in tandem with monoclonal antibodies to construct universal CAR-T cells, the weak affinity between them is one of the limiting factors for efficacy. Herein, we systematically investigated the impact of Fc receptor (Fc R) affinity on CAR-T cells properties by constructing universal CARs using Fc receptors with different affinities for IgG1 antibodies, namely CD16a, CD32a, and CD64. We demonstrated that the activities of these universal CAR-T cells on tumor cells could be redirected and regulated by IgG1 antibodies. In xenografted mice, 64CAR chimeric Jurkat cells with the highest affinity showed significant antitumor effects in combination with herceptin in the HER2 low expression U251 MG model. However, in the CD20 high expression Raji model, 64CAR caused excessive activation of CAR-T cells, which resulted in cytokine release syndrome (CRS) and the decline of antitumor activity, and 32CAR with a moderate affinity brought the best efficacy. Our work extended the knowledge about Fc R-based universal CAR-T cells and suggested that only the Fc RCAR with an appropriate affinity can offer the optimal antitumor advantages of CAR-T cells.
MEMBER ACCOUNT
登录成功会直接打开下一页。